logo-loader
viewVolitionRx

VolitionRX prices share offer at US$5 a pop

Shares in Volition closed at US$5.55 a share in New York.

Cancer
The company's Nu. Q colorectal cancer blood test should receive a European CE mark later this year.

Cancer diagnostics group VolitionRx Ltd (NYSEMKT:VNRX) said its previously-announced share offer has been priced at US$5 a share.

The life sciences company is set to raise around US$11.25mln through the underwritten public offer.

Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and for other general corporate purposes.

Shares in Volition currently trade at around US$5.55 a share in New York.

Quick facts: VolitionRx

Price: 4.62 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $189.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

4 days, 21 hours ago

2 min read